{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:21:07Z","timestamp":1757614867858,"version":"3.44.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Italian Ministry of Health, ricerca corrente, and Fondazione Roma"},{"DOI":"10.13039\/100031645","name":"Novartis Farma SpA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031645","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40123-025-01229-5","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T11:03:52Z","timestamp":1755687832000},"page":"2497-2510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodal Imaging to Assess Disease Activity and Predict Fluid Resolution in Patients with wAMD Treated with Brolucizumab: The IMAGINE Study"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04774926","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6817-2488","authenticated-orcid":false,"given":"Marco","family":"Lupidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stela","family":"Vujosevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariacristina","family":"Parravano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Bacherini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo Maria","family":"Minnella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Giansanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Ascardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Staurenghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"1229_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, et\u00a0al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106\u201316. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1.","journal-title":"Lancet Glob Health"},{"key":"1229_CR2","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S, et\u00a0al. Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221\u201334. https:\/\/doi.org\/10.1016\/S2214-109X(17)30393-5.","journal-title":"Lancet Glob Health"},{"key":"1229_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, et\u00a0al. Age-related macular degeneration. Lancet. 2018;392:1147\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(18)31550-2.","journal-title":"Lancet"},{"key":"1229_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.mam.2012.04.005","volume":"33","author":"I Bhutto","year":"2012","unstructured":"Bhutto I, Lutty G. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor\/retinal pigment epithelium\/Bruch\u2019s membrane\/choriocapillaris complex. Mol Aspects Med. 2012;33:295\u2013317. https:\/\/doi.org\/10.1016\/j.mam.2012.04.005.","journal-title":"Mol Aspects Med"},{"key":"1229_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ajo.2011.04.011","volume":"152","author":"F Sulzbacher","year":"2011","unstructured":"Sulzbacher F, Kiss C, Munk M, et\u00a0al. Diagnostic evaluation of type 2 (classic) choroidal neovascularization: optical coherence tomography, indocyanine green angiography, and fluorescein angiography. Am J Ophthalmol. 2011;152:799-806.e1. https:\/\/doi.org\/10.1016\/j.ajo.2011.04.011.","journal-title":"Am J Ophthalmol"},{"key":"1229_CR6","first-page":"06","volume":"6","author":"A Darwish","year":"2017","unstructured":"Darwish A. OCT angiography for the evaluation of wet age-related macular degeneration. EC Ophthalmol. 2017;6:06\u201318.","journal-title":"EC Ophthalmol"},{"key":"1229_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/IAE.0000000000001628","volume":"38","author":"M Al-Sheikh","year":"2018","unstructured":"Al-Sheikh M, Iafe NA, Phasukkijwatana N, et\u00a0al. Biomarkers of neovascular activity in age-related macular degeneration using optical coherence tomography angiography. Retina. 2018;38:220\u201330. https:\/\/doi.org\/10.1097\/IAE.0000000000001628.","journal-title":"Retina"},{"key":"1229_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, et\u00a0al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020;127:616\u201336. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004.","journal-title":"Ophthalmology"},{"key":"1229_CR9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.18553\/jmcp.2018.24.2-a.s3","volume":"24","author":"CC Wykoff","year":"2018","unstructured":"Wykoff CC, Clark WL, Nielsen JS, et\u00a0al. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm. 2018;24:S3\u201315. https:\/\/doi.org\/10.18553\/jmcp.2018.24.2-a.s3.","journal-title":"J Manag Care Spec Pharm"},{"key":"1229_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","volume":"127","author":"QD Nguyen","year":"2020","unstructured":"Nguyen QD, Das A, Do DV, et\u00a0al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127:963\u201376. https:\/\/doi.org\/10.1016\/j.ophtha.2019.12.031.","journal-title":"Ophthalmology"},{"key":"1229_CR11","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2147\/OPTH.S409103","volume":"17","author":"G Reitan","year":"2023","unstructured":"Reitan G, Kjellevold Haugen IB, Andersen K, et\u00a0al. Through the eyes of patients: understanding treatment burden of intravitreal anti-VEGF injections for nAMD patients in Norway. Clin Ophthalmol. 2023;17:1465\u201374. https:\/\/doi.org\/10.2147\/OPTH.S409103.","journal-title":"Clin Ophthalmol"},{"key":"1229_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, et\u00a0al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128:234\u201347. https:\/\/doi.org\/10.1016\/j.ophtha.2020.07.060.","journal-title":"Ophthalmology"},{"key":"1229_CR13","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, et\u00a0al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144\u201367. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305702.","journal-title":"Br J Ophthalmol"},{"key":"1229_CR14","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1172\/JCI71029","volume":"124","author":"FG Holz","year":"2014","unstructured":"Holz FG, Schmitz-Valckenberg S, Fleckenstein M. Recent developments in the treatment of age-related macular degeneration. J Clin Invest. 2014;124:1430\u20138. https:\/\/doi.org\/10.1172\/JCI71029.","journal-title":"J Clin Invest"},{"key":"1229_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, et\u00a0al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305327.","journal-title":"Br J Ophthalmol"},{"key":"1229_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, et\u00a0al. Hawk and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017.","journal-title":"Ophthalmology"},{"key":"1229_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502747","volume":"243","author":"J Mon\u00e9s","year":"2020","unstructured":"Mon\u00e9s J, Singh RP, Bandello F, et\u00a0al. Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset. Ophthalmologica. 2020;243:1\u20138. https:\/\/doi.org\/10.1159\/000502747.","journal-title":"Ophthalmologica"},{"key":"1229_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205513","volume":"13","author":"F Coscas","year":"2018","unstructured":"Coscas F, Cabral D, Pereira T, et\u00a0al. Quantitative optical coherence tomography angiography biomarkers for neovascular age-related macular degeneration in remission. PLoS ONE. 2018;13: e0205513. https:\/\/doi.org\/10.1371\/journal.pone.0205513.","journal-title":"PLoS ONE"},{"key":"1229_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19020820","volume":"19","author":"D Caballe-Fontanet","year":"2022","unstructured":"Caballe-Fontanet D, Alvarez-Peregrina C, Busquet-Duran N, et\u00a0al. Quality of life and anxiety in age macular degeneration patients: a cross-sectional study. Int J Environ Res Public Health. 2022;19: 820. https:\/\/doi.org\/10.3390\/ijerph19020820.","journal-title":"Int J Environ Res Public Health"},{"key":"1229_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011504","volume":"6","author":"DJ Taylor","year":"2016","unstructured":"Taylor DJ, Hobby AE, Binns AM, et\u00a0al. How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review. BMJ Open. 2016;6: e011504. https:\/\/doi.org\/10.1136\/bmjopen-2016-011504.","journal-title":"BMJ Open"},{"key":"1229_CR21","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mon\u00e9s","year":"2021","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ, et\u00a0al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1050\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2020.11.011.","journal-title":"Ophthalmology"},{"key":"1229_CR22","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.oret.2023.06.009","volume":"7","author":"B Bodaghi","year":"2023","unstructured":"Bodaghi B, Souied EH, Tadayoni R, et\u00a0al. Detection and management of intraocular inflammation after brolucizumab treatment for neovascular age-related macular degeneration. Ophthalmol Retina. 2023;7:879\u201391. https:\/\/doi.org\/10.1016\/j.oret.2023.06.009.","journal-title":"Ophthalmol Retina"},{"key":"1229_CR23","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40123-024-00920-3","volume":"13","author":"MA Zarbin","year":"2024","unstructured":"Zarbin MA, MacCumber MW, Karcher H, et\u00a0al. Real-world safety outcomes with brolucizumab in neovascular age-related macular degeneration: findings from the IRIS\u00ae registry. Ophthalmol Ther. 2024;13:1357\u201368. https:\/\/doi.org\/10.1007\/s40123-024-00920-3.","journal-title":"Ophthalmol Ther"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01229-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01229-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01229-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T10:41:10Z","timestamp":1757068870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01229-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01229-5","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"type":"print","value":"2193-8245"},{"type":"electronic","value":"2193-6528"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marco Lupidi serves as Advisory Board member for Abbvie, Apellis, Bayer, Novartis, and Roche. Mariacristina Parravano reports personal fees from Abbvie, Novartis, Bayer, and Roche outside of the submitted work. Francesco Bandello, Stela Vujosevic, Daniela Bacherini, Angelo Maria Minnella, Fabrizio Giansanti, Chiara Ascardi, and Giovanni Staurenghi have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines. The study protocol (EudraCT no. 2020\u2013002452-20) was reviewed and approved by the IRCCS Ospedale San Raffaele Ethics Committee in December 2020 (approval no. 332\/2020). The trial was registered with ClinicalTrials.gov (ClinicalTrials.gov ID NCT04774926).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}